产品
编 号：F479533
分子式：C19H29NO3
分子量：319.44
分子式：C19H29NO3
分子量：319.44
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 85081-18-1
产品详情
生物活性：
NBI-98782 is a high affinity and selectivity vesicular monoamine transporter 2 (VMAT2) inhibitor with a Ki of 3 nM. NBI-98782 has antipsychotic activity.
体内研究：
NBI-98782 (10 mg/kg，口服，每日 7 天) 可减少雄性 C57BL/6J 小鼠 mPFC 和 dSTR 中基础和 APD 诱导的单胺流出。Animal Model:Male C57BL/6J mice
Dosage:10 mg/kg
Administration:p.o., daily for 7 days
Result:Decreased the efflux of DA, 5-HT and NE in mPFC, dSTR, HIP and NAC.Increased the efflux of DOPAC, HVA, and 5-HIAA in mPFC, dSTR, HIP and NAC.Decreased in cortical DA and DOPAC as well as striatal DA, 5-HT and NE efflux combinated with haloperidol (HY-14538, 0.5 mg/kg, i.p.).Decreased cortical Glu and striatal ACh, DA and GABA efflux combinated with Clozapine (HY-14539, 10 mg/kg, i.p.).Reduced PCP-induced increase in LMA between various time points.Suppressed clozapine-, olanzapine- and risperidone-induced DA efflux in both mPFC and dSTR, and ACh efflux in mPFC.
NBI-98782 is a high affinity and selectivity vesicular monoamine transporter 2 (VMAT2) inhibitor with a Ki of 3 nM. NBI-98782 has antipsychotic activity.
体内研究：
NBI-98782 (10 mg/kg，口服，每日 7 天) 可减少雄性 C57BL/6J 小鼠 mPFC 和 dSTR 中基础和 APD 诱导的单胺流出。Animal Model:Male C57BL/6J mice
Dosage:10 mg/kg
Administration:p.o., daily for 7 days
Result:Decreased the efflux of DA, 5-HT and NE in mPFC, dSTR, HIP and NAC.Increased the efflux of DOPAC, HVA, and 5-HIAA in mPFC, dSTR, HIP and NAC.Decreased in cortical DA and DOPAC as well as striatal DA, 5-HT and NE efflux combinated with haloperidol (HY-14538, 0.5 mg/kg, i.p.).Decreased cortical Glu and striatal ACh, DA and GABA efflux combinated with Clozapine (HY-14539, 10 mg/kg, i.p.).Reduced PCP-induced increase in LMA between various time points.Suppressed clozapine-, olanzapine- and risperidone-induced DA efflux in both mPFC and dSTR, and ACh efflux in mPFC.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备